Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-1008 plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel in first-line metastatic or unresectable NSCLC
2007-004574-11Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Tigatuzumab + carboplatin/paclitaxel with Placebo + carboplatin/paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Dec 2007; status: completed.
02
Drugs
tigatuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-004574-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004574-11.